BP
BSX icon

Ballentine Partners’s Boston Scientific BSX Stock Holding History

Ballentine Partners’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$990K Sell
23,186
-5,535
-19% -$301K 0.01% 375
2026
Q1 		$1.8M Sell
28,721
-2,632
-8% -$211K 0.03% 221
2025
Q4 		$2.99M Sell
31,353
-1,274
-4% -$125K 0.04% 143
2025
Q3 		$3.19M Sell
32,627
-809
-2% -$83.8K 0.04% 135
2025
Q2 		$3.59M Buy
33,436
+175
+0.5% +$17.7K 0.05% 119
2025
Q1 		$3.36M Buy
33,261
+1,625
+5% +$164K 0.06% 115
2024
Q4 		$2.83M Buy
31,636
+2,248
+8% +$198K 0.05% 133
2024
Q3 		$2.46M Sell
29,388
-2,452
-8% -$193K 0.04% 148
2024
Q2 		$2.45M Buy
31,840
+4,779
+18% +$350K 0.05% 134
2024
Q1 		$1.85M Buy
27,061
+1,993
+8% +$128K 0.04% 162
2023
Q4 		$1.45M Buy
25,068
+1,059
+4% +$56.5K 0.03% 185
2023
Q3 		$1.27M Buy
24,009
+139
+0.6% +$7.29K 0.03% 172
2023
Q2 		$1.29M Buy
23,870
+770
+3% +$40.2K 0.03% 170
2023
Q1 		$1.16M Buy
23,100
+4,652
+25% +$219K 0.03% 181
2022
Q4 		$854K Buy
18,448
+10,100
+121% +$437K 0.03% 187
2022
Q3 		$323K Buy
8,348
+2,337
+39% +$93.8K 0.01% 324
2022
Q2 		$224K Buy
6,011
+107
+2% +$4.36K 0.01% 376
2022
Q1 		$261K Sell
5,904
-497
-8% -$21.5K 0.01% 382
2021
Q4 		$273K Buy
6,401
+873
+16% +$36.7K 0.01% 380
2021
Q3 		$240K Buy
5,528
+36
+0.7% +$1.59K 0.01% 367
2021
Q2 		$235K Sell
5,492
-188
-3% -$7.91K 0.01% 372
2021
Q1 		$219K Buy
+5,680
New +$215K 0.01% 361
2020
Q4 		– Sell
-8,970
Closed -$343K – 390
2020
Q3 		$343K Buy
8,970
+161
+2% +$6.2K 0.02% 263
2020
Q2 		$309K Sell
8,809
-1,525
-15% -$54.9K 0.01% 267
2020
Q1 		$336K Sell
10,334
-955
-8% -$37.3K 0.02% 234
2019
Q4 		$510K Buy
11,289
+104
+0.9% +$4.35K 0.02% 224
2019
Q3 		$455K Hold
11,185
– – 0.02% 217
2019
Q2 		$481K Buy
11,185
+1,974
+21% +$75.9K 0.02% 218
2019
Q1 		$354K Buy
9,211
+148
+2% +$5.65K 0.02% 228
2018
Q4 		$320K Buy
9,063
+2,758
+44% +$100K 0.02% 232
2018
Q3 		$243K Buy
6,305
+176
+3% +$6.15K 0.01% 296
2018
Q2 		$201K Buy
+6,129
New +$185K 0.01% 320

Other funds holding BSX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FFM
Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Ballentine Partners's BSX Position: Q2 2026 in Review

Ballentine Partners reduced its Boston Scientific (BSX) stake by 19% in Q2 2026, selling an estimated $301K and leaving 23,186 shares worth $990K. The position accounts for 0.01% of the portfolio, ranked #375.

Ballentine Partners first reported a position in BSX in Q2 2018 and has held it in 32 quarters since. The position peaked at $3.59M in Q2 2025. 179 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Ballentine Partners held 23,186 shares of Boston Scientific worth $990K as of Q2 2026.
  • Ballentine Partners sold 5,535 Boston Scientific shares in Q2 2026, an estimated $301K.
  • Boston Scientific made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #375 holding.
  • Ballentine Partners first reported a position in Boston Scientific in Q2 2018 and has held it in 32 quarters since.
  • Ballentine Partners's Boston Scientific position peaked at $3.59M in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.